Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells $15,075.94 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 5,423 shares of Sight Sciences stock in a transaction on Friday, January 17th. The stock was sold at an average price of $2.78, for a total transaction of $15,075.94. Following the transaction, the chief technology officer now directly owns 1,744,118 shares of the company’s stock, valued at $4,848,648.04. This represents a 0.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

David Badawi also recently made the following trade(s):

• On Wednesday, January 8th, David Badawi sold 3,829 shares of Sight Sciences stock. The shares were sold at an average price of $3.26, for a total transaction of $12,482.54.
• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The stock was sold at an average price of $3.52, for a total value of $10,950.72.

Sight Sciences Price Performance

Shares of SGHT opened at $2.88 on Thursday. The business’s fifty day moving average is $3.57 and its 200 day moving average is $5.33. Sight Sciences, Inc. has a 12-month low of $2.67 and a 12-month high of $8.45. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. The stock has a market cap of $146.17 million, a P/E ratio of -2.82 and a beta of 2.57.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. The firm had revenue of $20.16 million for the quarter, compared to analyst estimates of $20.41 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. Sell-side analysts anticipate that Sight Sciences, Inc. will post -1.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on SGHT shares. Piper Sandler reaffirmed a “neutral” rating and set a $5.50 target price (down previously from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Lake Street Capital reduced their price objective on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating for the company in a research report on Wednesday, January 15th. Citigroup dropped their target price on shares of Sight Sciences from $5.80 to $4.60 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a report on Tuesday, January 14th. Finally, Morgan Stanley decreased their price target on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Sight Sciences has a consensus rating of “Hold” and an average target price of $4.72.

Hedge Funds Weigh In On Sight Sciences

A number of hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC raised its stake in shares of Sight Sciences by 47.6% in the fourth quarter. SG Americas Securities LLC now owns 17,622 shares of the company’s stock worth $64,000 after purchasing an additional 5,681 shares during the last quarter. American Century Companies Inc. grew its holdings in Sight Sciences by 31.1% during the second quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock worth $240,000 after buying an additional 8,527 shares in the last quarter. B. Riley Wealth Advisors Inc. raised its position in Sight Sciences by 5.4% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company’s stock valued at $1,174,000 after buying an additional 10,000 shares during the last quarter. Rhumbline Advisers raised its position in Sight Sciences by 40.1% in the 2nd quarter. Rhumbline Advisers now owns 40,811 shares of the company’s stock valued at $272,000 after buying an additional 11,671 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Sight Sciences by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock valued at $4,941,000 after acquiring an additional 12,709 shares in the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.